DARPP-32 Promotes ERBB3-Mediated Resistance to Molecular Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma

Scientists showed that dopamine and cyclic AMP-regulated phosphoprotein, Mr 32000 physically recruited ERBB3 to epidermal growth factor receptor (EGFR) to mediate switching from EGFR homodimers to EGFR:ERBB3 heterodimers to bypass EGFR tyrosine kinase inhibitor -mediated inhibition by potentiating ERBB3-dependent activation of oncogenic signaling.